Skip to main content
Premium Trial:

Request an Annual Quote

Life Science Insights Worldwide Therapeutic RNAi 2004-2014 Forecast and Analysis, Acuity Pharmaceuticals Cand5, and Mirus Online Store

Premium

Life Science Insights said it has published “Worldwide Therapeutic RNAi 2004-2014 Forecast and Analysis,” an analysis of the RNAi-based drugs market.

According to the company, the report includes an overview of RNAi technologies and a 10-year market forecast.

“The RNAi therapeutic market will grow to over $10 billion by 2014 if the first few RNAi therapies are successful in human clinical trials, which will start later this year,” Life Science Insights senior research editor Zachary Zimmerman said in a statement released this week.


Acuity Pharmaceuticals said earlier this month that it has already begun a phase I trial of its siRNA-based age-related macular degeneration drug Cand5.


Mirus has recently launched an online store.

All of the Mirus’ reagent products, including its TransIt nucleic acid delivery and Label It nucleic acid labeling technologies, can now be purchased on the company’s website.

Additional information can be found at http://www.mirusbiocorporation.com/Merchant2/merchant.mv?Screen=SFNT&Store_Code=MBC.

 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.